ALPRAZOLAM

Alprazolam Adverse Events Reported to the FDA Over Time

How are Alprazolam adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Alprazolam, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Alprazolam is flagged as the suspect drug causing the adverse event.

Most Common Alprazolam Adverse Events Reported to the FDA

What are the most common Alprazolam adverse events reported to the FDA?

Completed Suicide	2179 (7.6%)
Cardiac Arrest	1465 (5.11%)
Respiratory Arrest	1450 (5.06%)
Cardio-respiratory Arrest	757 (2.64%)
Drug Abuse	693 (2.42%)
Poisoning	643 (2.24%)
Death	537 (1.87%)
Drug Ineffective	513 (1.79%)
Drug Toxicity	453 (1.58%)
Intentional Drug Misuse	391 (1.36%)
Anxiety	382 (1.33%)
	Show More
Multiple Drug Overdose	291 (1.01%)
Overdose	275 (.96%)
Suicide Attempt	260 (.91%)
Somnolence	255 (.89%)
Multiple Drug Overdose Intentional	238 (.83%)
Insomnia	232 (.81%)
Intentional Overdose	207 (.72%)
Depression	177 (.62%)
Nausea	175 (.61%)
Tremor	173 (.6%)
Headache	170 (.59%)
Fatigue	164 (.57%)
Dyspnoea	162 (.56%)
Malaise	161 (.56%)
Dizziness	152 (.53%)
Drug Interaction	141 (.49%)
Coma	138 (.48%)
Asthenia	136 (.47%)
Drug Dependence	131 (.46%)
Panic Attack	131 (.46%)
Agitation	124 (.43%)
Feeling Abnormal	123 (.43%)
Vomiting	119 (.41%)
Confusional State	118 (.41%)
Loss Of Consciousness	115 (.4%)
Nervousness	113 (.39%)
Fall	110 (.38%)
Diarrhoea	107 (.37%)
Unresponsive To Stimuli	103 (.36%)
Drug Withdrawal Syndrome	101 (.35%)
Depressed Level Of Consciousness	99 (.35%)
Convulsion	95 (.33%)
Incorrect Dose Administered	91 (.32%)
Oedema Peripheral	89 (.31%)
Pain	89 (.31%)
Withdrawal Syndrome	89 (.31%)
Drug Abuser	86 (.3%)
Condition Aggravated	85 (.3%)
Disorientation	84 (.29%)
Weight Increased	82 (.29%)
Drug Exposure During Pregnancy	81 (.28%)
Heart Rate Increased	81 (.28%)
Hypotension	81 (.28%)
Suicidal Ideation	81 (.28%)
Amnesia	78 (.27%)
Sedation	77 (.27%)
Poisoning Deliberate	76 (.26%)
Drug Effect Decreased	73 (.25%)
Hyperhidrosis	73 (.25%)
Pulmonary Oedema	71 (.25%)
Constipation	70 (.24%)
Gait Disturbance	70 (.24%)
Hypertension	70 (.24%)
Blood Pressure Increased	69 (.24%)
Abdominal Discomfort	67 (.23%)
Palpitations	67 (.23%)
Rash	65 (.23%)
Irritability	62 (.22%)
Restlessness	61 (.21%)
Product Substitution Issue	60 (.21%)
Accidental Death	58 (.2%)
Vision Blurred	58 (.2%)
Accidental Overdose	57 (.2%)
Abdominal Pain	56 (.2%)
Abnormal Behaviour	56 (.2%)
Substance Abuse	56 (.2%)
Weight Decreased	56 (.2%)
Medication Error	55 (.19%)
Sleep Disorder	55 (.19%)
Blood Glucose Increased	54 (.19%)
Pyrexia	54 (.19%)
Decreased Appetite	53 (.18%)
Mental Status Changes	53 (.18%)
Multiple Drug Overdose Accidental	53 (.18%)
Chest Pain	52 (.18%)
Hallucination	52 (.18%)
Hypersensitivity	52 (.18%)
Muscle Spasms	52 (.18%)
Back Pain	51 (.18%)
Delirium	51 (.18%)
Bradycardia	50 (.17%)
Electrocardiogram Qt Prolonged	50 (.17%)
Pain In Extremity	50 (.17%)
Serotonin Syndrome	50 (.17%)
Fear	49 (.17%)
Pulmonary Congestion	48 (.17%)
Sopor	48 (.17%)
Treatment Noncompliance	48 (.17%)
Memory Impairment	47 (.16%)
Thrombocytopenia	47 (.16%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Alprazolam, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Alprazolam is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Alprazolam

What are the most common Alprazolam adverse events reported to the FDA?

Suicidal And Self-injurious Behavio...	2581 (9%)
Cardiac Arrhythmias	2538 (8.85%)
Respiratory	2007 (7%)
Neurological	1558 (5.43%)
Medication Errors	1500 (5.23%)
Psychiatric	1493 (5.21%)
Chemical Injury And Poisoning	1314 (4.58%)
Therapeutic And Nontherapeutic Effe...	1008 (3.51%)
Anxiety Disorders	962 (3.35%)
Gastrointestinal Signs	636 (2.22%)
Fatal Outcomes	629 (2.19%)
	Show More
Sleep Disorders	419 (1.46%)
Movement Disorders	399 (1.39%)
Injuries	377 (1.31%)
Epidermal And Dermal Conditions	371 (1.29%)
Cardiac And Vascular Investigations	330 (1.15%)
Hepatic And Hepatobiliary	302 (1.05%)
Lifestyle Issues	280 (.98%)
Depressed Mood Disorders	263 (.92%)
Muscle	262 (.91%)
Deliria	257 (.9%)
Mental Impairment	212 (.74%)
Lower Respiratory Tract Disorders	210 (.73%)
Physical Examination Topics	206 (.72%)
Gastrointestinal Motility And Defec...	199 (.69%)
Disturbances In Thinking	194 (.68%)
Headaches	184 (.64%)
Infections - Pathogen Unspecified	183 (.64%)
Musculoskeletal And Connective Tiss...	183 (.64%)
Hematology Investigations	152 (.53%)
Cardiac Disorder Signs	148 (.52%)
Metabolic, Nutritional And Blood Ga...	146 (.51%)
Urinary Tract Signs	146 (.51%)
Product Quality Issues	141 (.49%)
Decreased And Nonspecific Blood Pre...	139 (.48%)
Hepatobiliary	139 (.48%)
Mood Disorders	138 (.48%)
Renal Disorders	131 (.46%)
Seizures	131 (.46%)
Skin Appendage Conditions	130 (.45%)
Vision	125 (.44%)
Ocular Neuromuscular	124 (.43%)
Toxicology And Therapeutic Drug Mon...	122 (.43%)
Allergic Conditions	120 (.42%)
Neuromuscular	116 (.4%)
Joint	108 (.38%)
Personality Disorders	107 (.37%)
Appetite And General Nutritional	102 (.36%)
Water, Electrolyte And Mineral	101 (.35%)
Electrolyte And Fluid Balance Condi...	100 (.35%)
Changes In Physical Activity	94 (.33%)
Myocardial	94 (.33%)
Encephalopathies	77 (.27%)
Psychiatric And Behavioural Symptom...	77 (.27%)
Therapeutic Procedures And Supporti...	76 (.26%)
Vascular Hypertensive	76 (.26%)
Body Temperature Conditions	75 (.26%)
White Blood Cell	70 (.24%)
Glucose Metabolism Disorders	68 (.24%)
Bone And Joint Injuries	65 (.23%)
Coronary Artery	65 (.23%)
Enzyme	64 (.22%)
Acid-base	62 (.22%)
Renal And Urinary Tract Investigati...	61 (.21%)
Legal Issues	54 (.19%)
Ocular Infections, Irritations And ...	49 (.17%)
Oral Soft Tissue Conditions	49 (.17%)
Platelet	47 (.16%)
Central Nervous System Vascular	46 (.16%)
Salivary Gland Conditions	43 (.15%)
Vascular Hemorrhagic	43 (.15%)
Bacterial Infectious	42 (.15%)
Gastrointestinal Conditions	42 (.15%)
Lipid Analyses	42 (.15%)
Obstetric And Gynecological Therape...	42 (.15%)
Bone And Joint Therapeutic Procedur...	40 (.14%)
Angiedema And Urticaria	39 (.14%)
Eye	38 (.13%)
Increased Intracranial Pressure And...	38 (.13%)
Vascular	38 (.13%)
Gastrointestinal Inflammatory Condi...	37 (.13%)
Manic And Bipolar Mood Disorders	37 (.13%)
Upper Respiratory Tract Disorders	37 (.13%)
Viral Infectious	37 (.13%)
Inner Ear And Viiith Cranial Nerve	35 (.12%)
Pleural	35 (.12%)
Arteriosclerosis, Stenosis, Vascula...	34 (.12%)
Bronchial Disorders	33 (.12%)
Sleep Disturbances	33 (.12%)
Tongue Conditions	32 (.11%)
Embolism And Thrombosis	30 (.1%)
Bone Disorders	29 (.1%)
Heart Failures	29 (.1%)
Abortions And Stillbirth	28 (.1%)
Hematological And Lymphoid Tissue T...	28 (.1%)
Neonatal Respiratory	28 (.1%)
Schizophrenia And Other Psychotic	28 (.1%)
Hearing	27 (.09%)
Protein And Amino Acid Metabolism	27 (.09%)
Anemias Nonhemolytic And Marrow Dep...	26 (.09%)
Coagulopathies And Bleeding Diathes...	25 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Alprazolam, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Alprazolam is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.